Back to Search Start Over

Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls

Authors :
Natalie E. Duran
Daniel W. Hommes
Source :
Therapeutic Advances in Gastroenterology, Vol 9 (2016)
Publication Year :
2016
Publisher :
SAGE Publishing, 2016.

Abstract

Inflammatory bowel disease (IBD) is a chronic, often relapsing, condition that deeply impacts the quality of life for many patients. Although there have been significant advances in medical treatments, a large proportion of patients become refractory to available therapeutic options. Stem-cell therapy through hematopoietic stem cells (HSCs) or mesenchymal stem (stromal) cells (MSCs) is a promising therapeutic option for severe refractory cases especially when surgery is not feasible. In HSC transplantation, the objective is to destroy the ‘autoreactive’ immune cells responsible for disease chronicity, and to re-establish gut tolerance to gut microbes. In perianal Crohn’s disease (CD), the objective is to deposit MSCs locally in fistulizing tracts to down-regulate the local immune response and induce wound healing. Results from upcoming and ongoing clinical trials will set the path of these novel therapeutic options that have the capability to successfully treat severe refractory Crohn’s patients.

Details

Language :
English
ISSN :
1756283X and 17562848
Volume :
9
Database :
Directory of Open Access Journals
Journal :
Therapeutic Advances in Gastroenterology
Publication Type :
Academic Journal
Accession number :
edsdoj.00a6c569e3fa4c29b0425046a422859d
Document Type :
article
Full Text :
https://doi.org/10.1177/1756283X16642190